Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon‐α
Objectives To evaluate the role of cytoreductive radiofrequency ablation (cRFA) in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with immuno‐ or targeted therapy. To assess the efficacy of sunitinib in patients with metastatic RCC with unresected small primar...
Gespeichert in:
| Veröffentlicht in: | BJU international 2013-07, Vol.112 (1), p.32-38 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 38 |
|---|---|
| container_issue | 1 |
| container_start_page | 32 |
| container_title | BJU international |
| container_volume | 112 |
| creator | Tsimafeyeu, Ilya Zart, Janie S. Chung, Bin |
| description | Objectives
To evaluate the role of cytoreductive radiofrequency ablation (cRFA) in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with immuno‐ or targeted therapy.
To assess the efficacy of sunitinib in patients with metastatic RCC with unresected small primary tumours.
Patients and Methods
Three parallel single‐arm prospective studies were conducted. Eligibility criteria were nearly identical for all trials and included: histopathologically confirmed RCC; metastatic measurable disease; size of primary tumour |
| doi_str_mv | 10.1111/bju.12107 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_bju_12107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>BJU12107</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2707-16bf6ac9a49fc954846de8261729bdc9c8008f7f27cd8153826b7f5683fd2a333</originalsourceid><addsrcrecordid>eNp1kE9O3TAQxq0KVP60i14AeYNUFg_sxM9OlhBBASEhVUXqLpo4Y2GUOK-206e34whcgSP0Ij1ET4Ihj7JiFjOjmZ_mG32EfOHskKc4au7GQ55xpj6QbS6kmAnOfm689qyUW2QnhDvG0kDOP5KtLFdCcpFtk8dqFQeP7aij_Y3UQ2sH4_HXiE6vKDQdRDs4ah1dpA5dDHRp4y3tMUKIaaSpRwcd1dilBF5bN_RAv36vqoMJDT2k1cLbHvyKxrEfRh9o9AgR2zUyOhutsw0dfNKK6A36wf27f_j75xPZNNAF_Lyuu-Tm7PRHdT67uv52UR1fzXSmmJpx2RgJugRRGl3ORSFki0UmucrKptWlLhgrjDKZ0m3B53laNcrMZZGbNoM8z3fJwXRX-yEEj6Zev1xzVj_bXCeb6xebE7s3sYux6bH9T776moD9NQBBQ2c8OG3DG6dEXpb8WfRo4pa2w9X7ivXJ5c0k_QR-FZmh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon‐α</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Tsimafeyeu, Ilya ; Zart, Janie S. ; Chung, Bin</creator><creatorcontrib>Tsimafeyeu, Ilya ; Zart, Janie S. ; Chung, Bin</creatorcontrib><description>Objectives
To evaluate the role of cytoreductive radiofrequency ablation (cRFA) in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with immuno‐ or targeted therapy.
To assess the efficacy of sunitinib in patients with metastatic RCC with unresected small primary tumours.
Patients and Methods
Three parallel single‐arm prospective studies were conducted. Eligibility criteria were nearly identical for all trials and included: histopathologically confirmed RCC; metastatic measurable disease; size of primary tumour <5 cm; good or intermediate prognosis according to the Memorial Sloan‐Kettering Cancer Center model; and no previous therapy.
Study 1: Patients were treated with percutaneous cRFA under computed tomography guidance followed by interferon (IFN)‐α, 9 MIU, s.c., three times per week. Study 2: Patients received cRFA followed by sunitinib in repeated 6‐week cycles of 50 mg/day orally for 4 weeks, then 2 weeks off treatment. Study 3: Patients with unresected primary RCC received sunitinib alone. The primary endpoint was progression‐free survival (PFS).
Results
Baseline patient characteristics (age, gender, histology, Eastern Cooperative Oncology Group performance status, metastatic sites, primary tumour size) were similar in all three studies.
Efficacy data for 114 evaluable patients showed an objective response rate of 8% (95% confidence interval [CI] 4.5, 10.5) for study 1, 28.9% (95% CI 15.2, 34) for study 2, and 31.6% (95% CI 20.3, 38.9) for study 3. The median (95% CI) PFS times were 9.1 (6.9, 10.2), 13.4 (9.8, 14.4) and 12.7 (11.3, 13.5) months for studies 1, 2 and 3, respectively.
Objective response rate was significantly higher and PFS significantly longer in the sunitinib trials than in study 1 (P < 0.01 all differences); no differences were found between studies 2 and 3 (objective response rate, P = 0.1; PFS, P = 0.6). Study 1 met its primary endpoint, showing that PFS was significantly longer than the expected 5 months (P = 0.02).
The median (95% CI) overall survival (OS) times were greater in study 2 (cRFA/sunitinib) and study 3 (sunitinib‐alone) than in study 1 (IFN‐α) at 27.2 (22.6, 31.8) and 22.5 (20.7, 24.3) vs 19.5 (16.3, 22.7) months, respectively. Differences were significant (study 1 vs 2, hazard ratio [HR] = 0.55; P = 0.003; study 1 vs study 3 HR = 0.6, P = 0.01). OS was significantly longer in the cRFA/sunitinib group compared with the sunitinib‐alone group (HR = 0.71; P = 0.04).
There were no unexpected toxicities of medical treatment or complications of cRFA.
Conclusions
cRFA is a safe and effective approach for select patients with metastatic RCC treated with immunotherapy.
The cRFA technique did not improve PFS in patients treated with sunitinib; cRFA probably has impact on OS in these patients. This needs to be tested in a larger trial.
Sunitinib was effective in patients with metastatic RCC with unresected small primary tumours.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/bju.12107</identifier><identifier>PMID: 23746142</identifier><language>eng</language><publisher>Oxford: Wiley-Blackwell</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Carcinoma, Renal Cell - diagnosis ; Carcinoma, Renal Cell - secondary ; Carcinoma, Renal Cell - therapy ; Catheter Ablation - methods ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Immunologic Factors - therapeutic use ; Indoles - therapeutic use ; Interferon-alpha - therapeutic use ; interferon‐α ; Kidney Neoplasms - pathology ; Kidney Neoplasms - therapy ; Male ; metastatic renal cell carcinoma ; Middle Aged ; Neoplasm Staging ; Prospective Studies ; Pyrroles - therapeutic use ; radiofrequency ablation ; small primary tumour ; sunitinib ; Treatment Outcome</subject><ispartof>BJU international, 2013-07, Vol.112 (1), p.32-38</ispartof><rights>2013 BJU International</rights><rights>2014 INIST-CNRS</rights><rights>2013 BJU International.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2707-16bf6ac9a49fc954846de8261729bdc9c8008f7f27cd8153826b7f5683fd2a333</citedby><cites>FETCH-LOGICAL-c2707-16bf6ac9a49fc954846de8261729bdc9c8008f7f27cd8153826b7f5683fd2a333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbju.12107$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbju.12107$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27439913$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23746142$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsimafeyeu, Ilya</creatorcontrib><creatorcontrib>Zart, Janie S.</creatorcontrib><creatorcontrib>Chung, Bin</creatorcontrib><title>Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon‐α</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Objectives
To evaluate the role of cytoreductive radiofrequency ablation (cRFA) in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with immuno‐ or targeted therapy.
To assess the efficacy of sunitinib in patients with metastatic RCC with unresected small primary tumours.
Patients and Methods
Three parallel single‐arm prospective studies were conducted. Eligibility criteria were nearly identical for all trials and included: histopathologically confirmed RCC; metastatic measurable disease; size of primary tumour <5 cm; good or intermediate prognosis according to the Memorial Sloan‐Kettering Cancer Center model; and no previous therapy.
Study 1: Patients were treated with percutaneous cRFA under computed tomography guidance followed by interferon (IFN)‐α, 9 MIU, s.c., three times per week. Study 2: Patients received cRFA followed by sunitinib in repeated 6‐week cycles of 50 mg/day orally for 4 weeks, then 2 weeks off treatment. Study 3: Patients with unresected primary RCC received sunitinib alone. The primary endpoint was progression‐free survival (PFS).
Results
Baseline patient characteristics (age, gender, histology, Eastern Cooperative Oncology Group performance status, metastatic sites, primary tumour size) were similar in all three studies.
Efficacy data for 114 evaluable patients showed an objective response rate of 8% (95% confidence interval [CI] 4.5, 10.5) for study 1, 28.9% (95% CI 15.2, 34) for study 2, and 31.6% (95% CI 20.3, 38.9) for study 3. The median (95% CI) PFS times were 9.1 (6.9, 10.2), 13.4 (9.8, 14.4) and 12.7 (11.3, 13.5) months for studies 1, 2 and 3, respectively.
Objective response rate was significantly higher and PFS significantly longer in the sunitinib trials than in study 1 (P < 0.01 all differences); no differences were found between studies 2 and 3 (objective response rate, P = 0.1; PFS, P = 0.6). Study 1 met its primary endpoint, showing that PFS was significantly longer than the expected 5 months (P = 0.02).
The median (95% CI) overall survival (OS) times were greater in study 2 (cRFA/sunitinib) and study 3 (sunitinib‐alone) than in study 1 (IFN‐α) at 27.2 (22.6, 31.8) and 22.5 (20.7, 24.3) vs 19.5 (16.3, 22.7) months, respectively. Differences were significant (study 1 vs 2, hazard ratio [HR] = 0.55; P = 0.003; study 1 vs study 3 HR = 0.6, P = 0.01). OS was significantly longer in the cRFA/sunitinib group compared with the sunitinib‐alone group (HR = 0.71; P = 0.04).
There were no unexpected toxicities of medical treatment or complications of cRFA.
Conclusions
cRFA is a safe and effective approach for select patients with metastatic RCC treated with immunotherapy.
The cRFA technique did not improve PFS in patients treated with sunitinib; cRFA probably has impact on OS in these patients. This needs to be tested in a larger trial.
Sunitinib was effective in patients with metastatic RCC with unresected small primary tumours.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Renal Cell - diagnosis</subject><subject>Carcinoma, Renal Cell - secondary</subject><subject>Carcinoma, Renal Cell - therapy</subject><subject>Catheter Ablation - methods</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Indoles - therapeutic use</subject><subject>Interferon-alpha - therapeutic use</subject><subject>interferon‐α</subject><subject>Kidney Neoplasms - pathology</subject><subject>Kidney Neoplasms - therapy</subject><subject>Male</subject><subject>metastatic renal cell carcinoma</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prospective Studies</subject><subject>Pyrroles - therapeutic use</subject><subject>radiofrequency ablation</subject><subject>small primary tumour</subject><subject>sunitinib</subject><subject>Treatment Outcome</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE9O3TAQxq0KVP60i14AeYNUFg_sxM9OlhBBASEhVUXqLpo4Y2GUOK-206e34whcgSP0Ij1ET4Ihj7JiFjOjmZ_mG32EfOHskKc4au7GQ55xpj6QbS6kmAnOfm689qyUW2QnhDvG0kDOP5KtLFdCcpFtk8dqFQeP7aij_Y3UQ2sH4_HXiE6vKDQdRDs4ah1dpA5dDHRp4y3tMUKIaaSpRwcd1dilBF5bN_RAv36vqoMJDT2k1cLbHvyKxrEfRh9o9AgR2zUyOhutsw0dfNKK6A36wf27f_j75xPZNNAF_Lyuu-Tm7PRHdT67uv52UR1fzXSmmJpx2RgJugRRGl3ORSFki0UmucrKptWlLhgrjDKZ0m3B53laNcrMZZGbNoM8z3fJwXRX-yEEj6Zev1xzVj_bXCeb6xebE7s3sYux6bH9T776moD9NQBBQ2c8OG3DG6dEXpb8WfRo4pa2w9X7ivXJ5c0k_QR-FZmh</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>Tsimafeyeu, Ilya</creator><creator>Zart, Janie S.</creator><creator>Chung, Bin</creator><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201307</creationdate><title>Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon‐α</title><author>Tsimafeyeu, Ilya ; Zart, Janie S. ; Chung, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2707-16bf6ac9a49fc954846de8261729bdc9c8008f7f27cd8153826b7f5683fd2a333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Renal Cell - diagnosis</topic><topic>Carcinoma, Renal Cell - secondary</topic><topic>Carcinoma, Renal Cell - therapy</topic><topic>Catheter Ablation - methods</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Indoles - therapeutic use</topic><topic>Interferon-alpha - therapeutic use</topic><topic>interferon‐α</topic><topic>Kidney Neoplasms - pathology</topic><topic>Kidney Neoplasms - therapy</topic><topic>Male</topic><topic>metastatic renal cell carcinoma</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prospective Studies</topic><topic>Pyrroles - therapeutic use</topic><topic>radiofrequency ablation</topic><topic>small primary tumour</topic><topic>sunitinib</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsimafeyeu, Ilya</creatorcontrib><creatorcontrib>Zart, Janie S.</creatorcontrib><creatorcontrib>Chung, Bin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsimafeyeu, Ilya</au><au>Zart, Janie S.</au><au>Chung, Bin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon‐α</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2013-07</date><risdate>2013</risdate><volume>112</volume><issue>1</issue><spage>32</spage><epage>38</epage><pages>32-38</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>Objectives
To evaluate the role of cytoreductive radiofrequency ablation (cRFA) in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with immuno‐ or targeted therapy.
To assess the efficacy of sunitinib in patients with metastatic RCC with unresected small primary tumours.
Patients and Methods
Three parallel single‐arm prospective studies were conducted. Eligibility criteria were nearly identical for all trials and included: histopathologically confirmed RCC; metastatic measurable disease; size of primary tumour <5 cm; good or intermediate prognosis according to the Memorial Sloan‐Kettering Cancer Center model; and no previous therapy.
Study 1: Patients were treated with percutaneous cRFA under computed tomography guidance followed by interferon (IFN)‐α, 9 MIU, s.c., three times per week. Study 2: Patients received cRFA followed by sunitinib in repeated 6‐week cycles of 50 mg/day orally for 4 weeks, then 2 weeks off treatment. Study 3: Patients with unresected primary RCC received sunitinib alone. The primary endpoint was progression‐free survival (PFS).
Results
Baseline patient characteristics (age, gender, histology, Eastern Cooperative Oncology Group performance status, metastatic sites, primary tumour size) were similar in all three studies.
Efficacy data for 114 evaluable patients showed an objective response rate of 8% (95% confidence interval [CI] 4.5, 10.5) for study 1, 28.9% (95% CI 15.2, 34) for study 2, and 31.6% (95% CI 20.3, 38.9) for study 3. The median (95% CI) PFS times were 9.1 (6.9, 10.2), 13.4 (9.8, 14.4) and 12.7 (11.3, 13.5) months for studies 1, 2 and 3, respectively.
Objective response rate was significantly higher and PFS significantly longer in the sunitinib trials than in study 1 (P < 0.01 all differences); no differences were found between studies 2 and 3 (objective response rate, P = 0.1; PFS, P = 0.6). Study 1 met its primary endpoint, showing that PFS was significantly longer than the expected 5 months (P = 0.02).
The median (95% CI) overall survival (OS) times were greater in study 2 (cRFA/sunitinib) and study 3 (sunitinib‐alone) than in study 1 (IFN‐α) at 27.2 (22.6, 31.8) and 22.5 (20.7, 24.3) vs 19.5 (16.3, 22.7) months, respectively. Differences were significant (study 1 vs 2, hazard ratio [HR] = 0.55; P = 0.003; study 1 vs study 3 HR = 0.6, P = 0.01). OS was significantly longer in the cRFA/sunitinib group compared with the sunitinib‐alone group (HR = 0.71; P = 0.04).
There were no unexpected toxicities of medical treatment or complications of cRFA.
Conclusions
cRFA is a safe and effective approach for select patients with metastatic RCC treated with immunotherapy.
The cRFA technique did not improve PFS in patients treated with sunitinib; cRFA probably has impact on OS in these patients. This needs to be tested in a larger trial.
Sunitinib was effective in patients with metastatic RCC with unresected small primary tumours.</abstract><cop>Oxford</cop><pub>Wiley-Blackwell</pub><pmid>23746142</pmid><doi>10.1111/bju.12107</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2013-07, Vol.112 (1), p.32-38 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_bju_12107 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Carcinoma, Renal Cell - diagnosis Carcinoma, Renal Cell - secondary Carcinoma, Renal Cell - therapy Catheter Ablation - methods Disease-Free Survival Female Follow-Up Studies Humans Immunologic Factors - therapeutic use Indoles - therapeutic use Interferon-alpha - therapeutic use interferon‐α Kidney Neoplasms - pathology Kidney Neoplasms - therapy Male metastatic renal cell carcinoma Middle Aged Neoplasm Staging Prospective Studies Pyrroles - therapeutic use radiofrequency ablation small primary tumour sunitinib Treatment Outcome |
| title | Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon‐α |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T20%3A39%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytoreductive%20radiofrequency%20ablation%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma%20(RCC)%20with%20small%20primary%20tumours%20treated%20with%20sunitinib%20or%20interferon%E2%80%90%CE%B1&rft.jtitle=BJU%20international&rft.au=Tsimafeyeu,%20Ilya&rft.date=2013-07&rft.volume=112&rft.issue=1&rft.spage=32&rft.epage=38&rft.pages=32-38&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/bju.12107&rft_dat=%3Cwiley_cross%3EBJU12107%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23746142&rfr_iscdi=true |